Arcade Therapeutics

Here is a fact that Raj Amin cannot stop thinking about, and once you hear it you will not stop thinking about it either: roughly two-thirds of Americans play video games, and almost none of them go to therapy. These are not the same people, exactly, but the overlap is enormous, and it contains a very large number of anxious people staring at their phones several hours a day, doing nothing that a clinician would recognize as treatment.

Amin's company, Arcade Therapeutics, is a bet that this is a distribution problem disguised as a health problem. The pitch is almost suspiciously simple. What if the game was the treatment? What if the thing that already has your attention could quietly do the thing you would otherwise have to pay a therapist for?

The technical answer to that question is a mouthful - attention bias modification, or ABM - and the marketing answer is a friendlier app called StarStarter. Both refer to the same underlying idea, which is that anxiety is, in part, a bad habit of attention. Anxious brains snap toward threat. They notice the frown in the crowd, the ambiguous email, the worst reading of every situation. ABM is a training regimen that gently, repeatedly nudges attention away from threat and toward neutral - and it turns out you can smuggle that regimen inside gameplay so thoroughly that the patient mostly experiences it as a game.

The rebrand as thesis statement

The company was originally named Wise Therapeutics. That is a fine name for a company that wants you to trust its science. It is a terrible name for a company whose entire strategy depends on you actually enjoying the product. So Wise became Arcade, and the repositioning tells you almost everything: this is a science-first game studio that happens to run randomized controlled trials, rather than a pharma outfit that happens to ship an app.

That distinction matters because the failure mode of digital health is not usually bad science. It is that nobody opens the app twice. Adherence - the unglamorous question of whether people actually do the thing - is the graveyard where most wellness apps quietly die. Arcade's wager is that games are the best engagement technology humans have ever built, and that if you make the medicine genuinely fun, the adherence problem stops being a problem you have to solve.

The part where the data shows up

It would be easy to file all of this under "plausible startup story" if not for a small, stubborn detail: in March 2025 the company published a randomized controlled trial in the Journal of Anxiety Disorders. The study enrolled 104 participants with social anxiety disorder. Over 90% saw reduced symptoms. The average reduction was about 33%. More than two-thirds reached what researchers call a clinically meaningful improvement, and more than a third dropped to sub-clinical levels within a month.

The trial was also, notably, honest about itself. The control group did not sit idle - they played the same game in a "placebo mode" that delivered roughly half the active training effect. That is a hard test to design and a harder one to pass, because it means the game had to beat a very convincing version of itself. It did, with a statistically significant edge over placebo.

Two founders, one strange premise

The company is co-founded by Amin, a serial healthcare entrepreneur, and Tracy Dennis-Tiwary, a neuroscientist who wrote a book with the wonderfully contrarian title Future Tense: Why Anxiety Is Good for You (Even Though It Feels Bad). This is not a throwaway biographical fact. Dennis-Tiwary's whole scientific stance is that anxiety is not a bug to be deleted but a signal to be retrained - which is precisely what ABM tries to do. It does not promise to make you fearless. It tries to loosen the reflex that turns ordinary worry into a spiral.

Amin, for his part, has done a version of this before. He co-founded HealthiNation, an on-demand health video network that reached more than 100 million monthly viewers before being acquired by GoodRx, and Mana Health, later acquired by Comcast. His recurring trick is taking a serious health idea and wrapping it in a consumer format people will voluntarily touch. Arcade is that instinct pointed at the FDA.

Why now, and who pays

The unsexy tailwind here is reimbursement. Digital therapeutics only work as a business if someone other than the patient will pay, and starting in 2025 the Centers for Medicare & Medicaid Services began rolling out billing codes for digital mental health treatments. That single regulatory development is what lets Arcade credibly describe its products as prescription digital therapeutics - things a doctor can order and an insurer can cover - rather than another app in the wellness bin.

The pipeline reflects the ambition. Beyond StarStarter and its prescription counterpart ABM-01 for social anxiety, the company won a $3.8M National Institute of Mental Health grant, alongside the University of Texas at Austin, to test ABM-02 for major depressive disorder. Further out sit targets for generalized anxiety, alcohol use disorder, and mental-health conditions tied to pregnancy and multiple sclerosis. It is a long road, and clinical trials do not care about your burn rate.

Which is the honest place to end. Arcade Therapeutics has real trial data, real grant money, and a genuinely clever answer to the oldest question in mental health - how do you get people to actually do the work. What it does not yet have is FDA clearance or scale, and the history of digital therapeutics is littered with companies that had the science and ran out of road before the market caught up. The interesting thing about Arcade is that it is betting the market has finally arrived. If it is right, your next anxiety prescription might come with a high score.